Differential expression of genes associated with pathological complete response (pCR) and residual disease
breast cancer-related
RESIDUAL DISEASE
Gene expression levels, using a panel of 776 breast cancer-related genes, were analyzed in pretreatment samples from the carboplatin + paclitaxel (n = 33) and paclitaxel (n = 33) arms. As shown in Fig. Heatmap of gene expression data using unsupervised hierarchical clustering to show the difference in expression between pCR and RD. Patients who achieved pCR are identified in orange and those with RD in gray. Each column indicates a sample, and each row represents a gene. Red indicates upregulation, and green indicates downregulation. (To test the hypothesis that differentially expressed genes could account for the differences in pCR between the study arms, we explored potential gene expression signatures predictive of pCR within each treatment arm. In the carboplatin arm, we identified 37 genes differentially expressed between the pCR and non-pCR groups (Fig. Boxplot genes predictive of pCR (only those that achieved statistical significance in each study arm in the first analysis). Patients who achieved pCR are identified in orange, and those who had residual disease are identified in gray. (